(NASDAQ:MESO) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (āInvestorsā) to issue, at its sole discretion, up to US$50.0 million (A$76.8 million)1 of unsecured convertible notes. The funding is available at Mesoblastās option, following shareholder approval, to repay or reduce the amount owing to its secured lenders under the existing loan agreements and for general working capital purposes.
Related Questions
How will the issuance of up to $50āÆmillion in convertible notes affect MESO's dilution and share price dynamics?
What are the terms (interest rate, conversion price, maturity) of the convertible notes and how do they compare to the company's existing debt structure?
How will the potential repayment of secured debt improve MESO's balance sheet and credit profile, and what impact might this have on the company's financing flexibility and valuation?